Cancer name Glioblastoma
Cancer Type GBM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment IFN-β
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature NKG2D
Official Symbol KLRK1
Mode of action PROT_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description While the expression of the activating immune cell receptor NKG2D was significantly up-regulated, DNAM–1 levels on NKL cells did not show any changes following stimulation with IFN-β.
PMID 26441059
Title Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells.